Creating engineered T cells to fight aggressive breast cancer
Development of CD4 TCR-engineered T cell immunotherapy in triple-negative breast cancer
['FUNDING_SBIR_2'] · IMMUNOVA THERAPEUTICS, LLC · NIH-11007018
This study is testing a new treatment for triple-negative breast cancer that uses specially modified immune cells to help your body fight the cancer better, and it's aimed at patients who haven't had success with other treatments.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | IMMUNOVA THERAPEUTICS, LLC (nih funded) |
| Locations | 1 site (MONROVIA, UNITED STATES) |
| Trial ID | NIH-11007018 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new type of immunotherapy using engineered T cells specifically designed to target triple-negative breast cancer (TNBC), which is known for its aggressive nature and limited treatment options. The approach involves creating CD4+ T cells that are modified to recognize and attack cancer cells more effectively. By enhancing the immune response against TNBC, the goal is to improve patient outcomes and provide a new therapeutic option for those who have not responded to existing treatments. Patients may be involved in trials to assess the safety and effectiveness of this innovative therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who have limited treatment options.
Not a fit: Patients with non-breast cancers or those whose tumors do not express the targeted antigens may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for patients with triple-negative breast cancer.
How similar studies have performed: Other research has shown promise in using engineered T cell therapies for various cancers, suggesting potential success for this approach in treating TNBC.
Where this research is happening
MONROVIA, UNITED STATES
- IMMUNOVA THERAPEUTICS, LLC — MONROVIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, YICHENG — IMMUNOVA THERAPEUTICS, LLC
- Study coordinator: WANG, YICHENG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer